Clean Cap

* CHF, excl. 8.1% VAT and shipping costs

Product Description

Messenger RNA (mRNA) serves numerous research and clinical purposes. It is produced through the transcription of a DNA template. In vitro transcription (IVT) of mRNA requires efficient capping strategies to generate biologically active and stable mRNA molecules. In mammalian cells, specific molecular structures are added to one end of an mRNA strand to shield it from degradation and ensure proper translation and function. This process is known as capping. Typically, both in vivo and in various lab procedures, the cap is attached after mRNA synthesis, referred to as post-transcriptional or enzymatic capping. This method necessitates additional enzymatic reactions and purification steps, increasing the complexity and duration of the process.TriLink Biotechnologies provides a co-transcriptional capping technology using the CleanCap® molecule, which offers a streamlined, one-pot solution that minimizes the number of steps and results in a cap-1 structure crucial for mRNA function. This, CleanCap®-AG Reagent (BCT-38) is a trinucleotide reagent containing the native cap structure and an A and G at the initial two positions of the mRNA.Conventional capping methods, such as the use of ARCA (anti-reverse cap analogue), sometimes face the problem of capping efficiency and